ThromboGenics NV
Gaston Geenslaan 1
Heverlee
B-3001
Tel: 32-0-16-751310
Fax: 32-0-16-751311
Website: http://www.thrombogenics.com/
Email: info@thrombogenics.com
110 articles about ThromboGenics NV
-
BioInvent And ThromboGenics NV Announce Positive Results from Phase II VTE Prophylaxis Study; Shows TB-402 Superior Antithrombotic Activity Compared to Sanofi-Aventis (France) Enoxaparin
7/9/2010
-
BioInvent And ThromboGenics NV Announce Positive Topline Results from Phase II VTE Prophylaxis Study with Anti-Factor VIII (TB-402)
5/6/2010
-
ThromboGenics NV Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for the Non-Surgical Treatment of Symptomatic Vitreomacular Adhesion (VMA)
4/20/2010
-
ThromboGenics NV: Positive Microplasmin Phase II Data Published in Ophthalmology
2/9/2010
-
ThromboGenics NV Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
12/16/2009
-
ThromboGenics NV Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
12/11/2009
-
BioInvent and ThromboGenics NV Win "Licensing Deal of the Year" at the Scrip Awards 2009
11/19/2009
-
ThromboGenics NV Q3 2009 Business Update
11/4/2009
-
ThromboGenics NV Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9/24/2009
-
ThromboGenics NV Announces Business Update and Half Year Results 2009
8/27/2009